Jung Choi - 01 Sep 2021 Form 4 Insider Report for Global Blood Therapeutics, Inc.

Role
Chief Business and Strategy Officer
Signature
/s/ Miguel Carrillo, as Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
01 Sep 2021
Net transactions value
-$37,773
Form type
4
Filing time
03 Sep 2021, 20:01:09 UTC
Previous filing
24 Sep 2021
Next filing
03 Feb 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GBT Common Stock Award $3,122 +128 +0.07% $24.39 182,495 31 Aug 2021 Direct F1
transaction GBT Common Stock Options Exercise +2,762 +1.5% 185,257 01 Sep 2021 Direct F2
transaction GBT Common Stock Tax liability $40,894 -1,370 -0.74% $29.85 183,887 01 Sep 2021 Direct F3
holding GBT Common Stock 25,000 01 Sep 2021 By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GBT Restricted Stock Units Options Exercise $0 -2,762 -12% $0.000000 19,340 01 Sep 2021 Common Stock 2,762 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired pursuant to the Issuer's Amended and Restated 2015 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2 Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
F3 Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 2,762 shares of Common Stock underlying the Reporting Person's RSUs.
F4 The shares of Common Stock underlying the RSUs vest in 8 equal semi-annual installments over 4 years from March 1, 2021, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.

Remarks:

Chief Business and Strategy Officer